Trevi Therapeutics Schedules Investor Events Ahead of Key Data Presentations
Event summary
- Trevi Therapeutics will host an Investor and Analyst Day on May 7, 2026, in New York City.
- Jennifer Good (President & CEO) and David Hastings (CFO) will present at the Bank of America Global Healthcare Conference on May 12-13, 2026, in Las Vegas.
- A data highlights event featuring Philip Molyneaux and James Cassella will be held on May 18, 2026, in Orlando, coinciding with the ATS International Conference.
- Haduvio™ (oral nalbuphine ER) is being developed for chronic cough in IPF, non-IPF ILD, and RCC, targeting a combined patient population of roughly 370,000 U.S. patients.
The big picture
Trevi Therapeutics is attempting to address a significant unmet need in chronic cough management, a condition affecting a substantial patient population with limited treatment options. The company's reliance on clinical trial data and key opinion leader endorsements to drive investor confidence highlights the inherent risks associated with late-stage drug development. The upcoming events represent a critical juncture for the company to demonstrate the value proposition of Haduvio and secure future funding.
What we're watching
- Clinical Data
- The data presented at the ATS conference will be crucial in assessing Haduvio’s efficacy and safety profile, potentially influencing regulatory pathways and investor sentiment.
- Commercialization
- The success of Trevi’s investor outreach, particularly at the Analyst Day, will indicate the level of institutional interest and potential for future funding or partnerships.
- Regulatory Risk
- While nalbuphine is not currently scheduled by the DEA, any future changes in regulatory classification could significantly impact Haduvio’s commercial viability.
Related topics